Macquarie 13-Feb-13
Acrux's suite of patents just received another addition for underarm application of Axiron in the US. But it's not patents Macquarie analysts are concerned about. It's about market entrance of generic testosterone gels and their impact on Axiron's main competitors in the market.
Bottom line: Macquarie is anticipating an increasingly rougher market environment for the company ahead. This justifies the Underperform rating, even when the price target has moved up to $2.98 from $2.60 prior.
Current estimates anticipate a big jump in profitability (and dividends) in FY14.
Underperform
- Forums
- ASX - By Stock
- ACR
- shorters are they mad??
shorters are they mad??, page-13
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
First paediatric clinical site activated – major recruitment milestone and key appointment announced
NEWS
Exceptional lithium assays uncovered at Falcon Lake – expanding mineralisation, big potential ahead
Add ACR (ASX) to my watchlist
|
|||||
Last
5.8¢ |
Change
0.003(5.45%) |
Mkt cap ! $16.86M |
Open | High | Low | Value | Volume |
5.5¢ | 5.8¢ | 5.4¢ | $73.70K | 1.303M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 76865 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 101900 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 76865 | 0.056 |
1 | 35350 | 0.055 |
1 | 16012 | 0.054 |
1 | 18800 | 0.053 |
1 | 16012 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 101900 | 2 |
0.059 | 225945 | 1 |
0.060 | 115000 | 1 |
0.061 | 100000 | 1 |
0.062 | 116100 | 2 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |